Since high-level expression of SLAMF7 is retained in multiple myeloma (MM) cells, implicated in the uncontrolled proliferation of MM cells, the receptor is a promising target for immunotherapy [216]. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.